CWA Asset Management Group LLC Cuts Stock Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

CWA Asset Management Group LLC cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 11.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,642 shares of the specialty pharmaceutical company's stock after selling 2,963 shares during the quarter. CWA Asset Management Group LLC's holdings in Jazz Pharmaceuticals were worth $2,935,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of JAZZ. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $25,000. Quadrant Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP grew its holdings in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares in the last quarter. CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Allianz SE purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $29,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Down 0.7%

JAZZ traded down $0.73 during trading on Friday, reaching $107.51. The company had a trading volume of 1,053,788 shares, compared to its average volume of 830,550. The stock has a market cap of $6.51 billion, a P/E ratio of 14.33, a PEG ratio of 4.67 and a beta of 0.33. The business has a 50 day simple moving average of $108.14 and a 200-day simple moving average of $120.08. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm's quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.68 earnings per share. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price objective for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Morgan Stanley cut their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Finally, Royal Bank Of Canada cut their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $184.00.

Insider Buying and Selling

In other news, Director Seamus Mulligan acquired 1,621 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the acquisition, the director now directly owns 101,621 shares of the company's stock, valued at $10,466,963. The trade was a 1.62% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the sale, the chief executive officer now owns 439,307 shares of the company's stock, valued at $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,000 shares of company stock worth $355,925 over the last three months. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.